ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES ON A PHASE I CLINICAL STUDY AND A PHASEI/II CLINICAL STUDY OF JSKN003 FOR PRESENTATION AT ESMOCONGRESS 2024
ALPHAMAB-B: INSIDE INFORMATION ANNOUNCEMENT - UPDATES IN RELATION TO A PHASE III CLINICAL TRIAL OF KN046FOR THE TREATMENT OF ADVANCED SQ NSCLC
ALPHAMAB-B: (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
ALPHAMAB-B: Next Day Disclosure Return
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
ALPHAMAB-B: Next Day Disclosure Return
ALPHAMAB-B: CONNECTED TRANSACTION ANNOUNCEMENT -RENEWAL OF THE LEASE AGREEMENT
ALPHAMAB-B: Next Day Disclosure Return
ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE
ALPHAMAB-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
ALPHAMAB-B: DATE OF BOARD MEETING
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
ALPHAMAB-B: POLL RESULTS OF ANNUAL GENERAL MEETING HELD ONJUNE 12, 2024
ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - COLLABORATION WITH ARRIVENT IN RELATION TOTHE RESEARCH, DEVELOPMENT ANDCOMMERCIALIZATION OF ADC PRODUCTS
ALPHAMAB-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2024
ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES ON A PHASE I/II CLINICAL STUDY OF JSKN003FOR THE TREATMENT OF ADVANCED SOLID TUMORS FORPRESENTATION AT 2024 ASCO ANNUAL MEETING
ALPHAMAB-B: INSIDE INFORMATION ANNOUNCEMENT - UPDATES IN RELATION TO A PHASE III CLINICAL TRIAL OF KN046FOR THE TREATMENT OF ADVANCED PDAC
ALPHAMAB-B: Next Day Disclosure Return
ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT -FIRST PATIENT DOSED IN A PHASE I CLINICAL TRIAL OF JSKN016FOR THE TREATMENT OF ADVANCED MALIGNANT SOLID TUMORS
No Data
No Data